Neutralizing activity of anti-respiratory syncytial virus monoclonal antibody produced in Nicotiana benthamiana

References

• Rha B, Curns AT, Lively JY, Campbell AP, Englund JA, Boom JA, Azimi PH, Weinberg GA, Staat MA, Selvarangan R. Respiratory Syncytial Virus-Associated Hospitalizations Among Young Children: 2015-2016. Pediatrics. 2020;146(1):e20193611. doi:10.1542/peds.2019-3611.
   PubMed Web of Science ®Google Scholar
• Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588–10. doi:10.1056/NEJMoa0804877.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Increased interseasonal respiratory syncytial virus (RSV) activity in parts of the Southern United States. CDC Health Alert Network; 2021.
   Google Scholar
• Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005;352(17):1749–59. doi:10.1056/NEJMoa043951.
   PubMed Web of Science ®Google Scholar
• Shi T, McAllister DA, O’Brien KL, Simoes EAF, Madhi SA, Gessner BD, Polack FP, Balsells E, Acacio S, Aguayo C, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946–58. doi:10.1016/S0140-6736(17)30938-8.
   PubMed Web of Science ®Google Scholar
• Battles MB, McLellan JS. Respiratory syncytial virus entry and how to block it. Nat Rev Microbiol. 2019;17(4):233–45. doi:10.1038/s41579-019-0149-x.
   PubMed Web of Science ®Google Scholar
• Pandya MC, Callahan SM, Savchenko KG, Stobart CC. A contemporary view of respiratory syncytial virus (RSV) biology and strain-specific differences. Pathogens. 2019;8(2):67. doi:10.3390/pathogens8020067.
   PubMed Web of Science ®Google Scholar
• Patel N, Tian JH, Flores R, Jacobson K, Walker M, Portnoff A, Gueber-Xabier M, Massare MJ, Glenn G, Ellingsworth L et al. Flexible RSV prefusogenic fusion glycoprotein exposes multiple neutralizing epitopes that may collectively contribute to protective immunity. Vaccines (Basel). 2020;8:607.
   PubMed Web of Science ®Google Scholar
• Tang A, Chen Z, Cox KS, Su H-P, Callahan C, Fridman A, Zhang L, Patel SB, Cejas PJ, Swoyer R, et al. A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein. Nat Commun. 2019;10(1):4153. doi:10.1038/s41467-019-12137-1.
   PubMedGoogle Scholar
• McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GBE, Yang Y, Zhang B, Chen L, Srivatsan S, Zheng A, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science. 2013;342(6158):592–8. doi:10.1126/science.1243283.
   PubMed Web of Science ®Google Scholar
• McLellan JS, Yang Y, Graham BS, Kwong PD. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol. 2011;85(15):7788–96. doi:10.1128/JVI.00555-11.
   PubMed Web of Science ®Google Scholar
• Mousa JJ, Kose N, Matta P, Gilchuk P, Crowe JE. A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein. Nat Microbiol. 2017;2(4):16271. doi:10.1038/nmicrobiol.2016.271.
   PubMed Web of Science ®Google Scholar
• Hause AM, Henke DM, Avadhanula V, Shaw CA, Tapia LI, Piedra PA, Tregoning JS. Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B. PLoS One. 2017;12(4):e0175792. doi:10.1371/journal.pone.0175792.
   PubMed Web of Science ®Google Scholar
• Mas V, Nair H, Campbell H, Melero JA, Williams TC. Antigenic and sequence variability of the human respiratory syncytial virus F glycoprotein compared to related viruses in a comprehensive dataset. Vaccine. 2018;36(45):6660–73. doi:10.1016/j.vaccine.2018.09.056.
   PubMed Web of Science ®Google Scholar
• Papi A, Ison MG, Langley JM, Lee D-G, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Campora L, Dezutter N, et al. Respiratory syncytial virus prefusion F protein vaccine in older adults. N Engl J Med. 2023;388(7):595–608. doi:10.1056/NEJMoa2209604.
   PubMed Web of Science ®Google Scholar
• Viguria N, Navascués A, Juanbeltz R, Echeverría A, Ezpeleta C, Castilla J. Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children. Hum Vaccines Immunother. 2021;17(6):1867–72. doi:10.1080/21645515.2020.1843336.
   PubMed Web of Science ®Google Scholar
• Keam SJ. Nirsevimab: first approval. Drugs. 2023;83(2):181–7. doi:10.1007/s40265-022-01829-6.
   PubMed Web of Science ®Google Scholar
• Brady T, Cayatte C, Roe TL, Speer SD, Ji H, Machiesky L, Zhang T, Wilkins D, Tuffy KM, Kelly EJ, et al. Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection. Front Immunol. 2023;14:1283120. doi:10.3389/fimmu.2023.1283120.
   PubMed Web of Science ®Google Scholar
• Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, Muller WJ, Zar HJ, Brooks D, Grenham A, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022;386(9):837–46. doi:10.1056/NEJMoa2110275.
   PubMed Web of Science ®Google Scholar
• Tian D, Battles MB, Moin SM, Chen M, Modjarrad K, Kumar A, Kanekiyo M, Graepel KW, Taher NM, Hotard AL, et al. Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein. Nat Commun. 2017;8(1):1877. doi:10.1038/s41467-017-01858-w.
   PubMedGoogle Scholar
• Gilman M, Furmanova-Hollenstein P, Pascual G, Wout A, Langedijk J, McLellan J. Transient opening of trimeric prefusion RSV F proteins. Nat Commun. 2019;10(1):2105. doi:10.1038/s41467-019-09807-5.
   PubMedGoogle Scholar
• McLellan J, Chen M, Leung S, Graepel K, Du X, Yang Y, Zhou T, Baxa U, Yasuda E, Beaumont T, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science. 2013;340(6136):1113–17. doi:10.1126/science.1234914.
   PubMed Web of Science ®Google Scholar
• Chen Q, Davis K. The potential of plants as a system for the development and production of human biologics. F1000 Resear. 2016;5. doi:10.12688/f1000research.8010.1.
   Google Scholar
• Gerasimova SV, Smirnova OG, Kochetov AV, Shumnyi VK. Production of recombinant proteins in plant cells. Russ J Plant Physiol. 2016;63(1):26–37. doi:10.1134/S1021443716010076.
   Web of Science ®Google Scholar
• Twyman RM, Schillberg S, Fischer R. Transgenic plants in the biopharmaceutical market. Expert Opin Emerg Drugs. 2005;10(1):185–218. doi:10.1517/14728214.10.1.185.
   PubMedGoogle Scholar
• Sack M, Hofbauer A, Fischer R, Stoger E. The increasing value of plant-made proteins. Curr Opin Biotechnol. 2015;32:163–70. doi:10.1016/j.copbio.2014.12.008.
   PubMed Web of Science ®Google Scholar
• Dent M, Hurtado J, Paul AM, Sun H, Lai H, Yang M, Esqueda A, Bai F, Steinkellner H, Chen Q, et al. Plant-produced anti-dengue virus monoclonal antibodies exhibit reduced antibody-dependent enhancement of infection activity. J Gen Virol. 2016;97(12):3280–90. doi:10.1099/jgv.0.000635.
   PubMedGoogle Scholar
• Zhang Y, Li D, Jin X, Huang Z. Fighting ebola with ZMapp: spotlight on plant-made antibody. Sci China Life Sci. 2014;57(10):987–8. doi:10.1007/s11427-014-4746-7.
   PubMed Web of Science ®Google Scholar
• Shanmugaraj B, Rattanapisit K, Manopwisedjaroen S, Thitithanyanont A, Phoolcharoen W. Monoclonal antibodies B38 and H4 produced in Nicotiana benthamiana neutralize SARS-CoV-2 in vitro. Front Plant Sci. 2020;11:11. doi:10.3389/fpls.2020.589995.
   PubMed Web of Science ®Google Scholar
• Rattanapisit K, Shanmugaraj B, Manopwisedjaroen S, Purwono PB, Siriwattananon K, Khorattanakulchai N, Hanittinan O, Boonyayothin W, Thitithanyanont A, Smith DR, et al. Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in Nicotiana benthamiana. Sci Rep. 2020;10(1):17698. doi:10.1038/s41598-020-74904-1.
   PubMed Web of Science ®Google Scholar
• Nosaki S, Hoshikawa K, Ezura H, Miura K. Transient protein expression systems in plants and their applications. Plant Biotechnol (Tokyo). 2021;38(3):297–304. doi:10.5511/plantbiotechnology.21.0610a.
   PubMedGoogle Scholar
• Tyurin AA, Suhorukova AV, Kabardaeva KV, Goldenkova-Pavlova IV, Goldenkova-Pavlova IV. Transient gene expression is an effective experimental tool for the research into the fine mechanisms of plant gene function: advantages, limitations, and solutions. Plants. 2020;9(9):1187. doi:10.3390/plants9091187.
   Google Scholar
• SBaR S. Plant expression platform for the production of recombinant pharmaceutical proteins. Austin J Biotechnol Bioeng. 2014;1:1–4.
   Google Scholar
• Iyappan G, Shanmugaraj BM, Inchakalody V, Ma JKC, Ramalingam S. Potential of plant biologics to tackle the epidemic like situations – case studies involving viral and bacterial candidates. Int J Infect Dis. 2018;73:363. doi:10.1016/j.ijid.2018.04.4236.
   Web of Science ®Google Scholar
• He W, Baysal C, Lobato Gómez M, Huang X, Alvarez D, Zhu C, Armario‐Najera V, Blanco Perera A, Cerda Bennaser P, Saba‐Mayoral A, et al. Contributions of the international plant science community to the fight against infectious diseases in humans—part 2: affordable drugs in edible plants for endemic and re-emerging diseases. Plant Biotechnol J. 2021;19(10):1921–36. doi:10.1111/pbi.13658.
   PubMed Web of Science ®Google Scholar
• Shanmugaraj B, Jirarojwattana P, Phoolcharoen W. Molecular farming strategy for the rapid production of protein-based reagents for use in infectious disease diagnostics. Planta Med. 2023;89(10):1010–1020. doi:10.1055/a-2076-2034.
   PubMed Web of Science ®Google Scholar
• Shanmugaraj B, Bulaon CJ, Phoolcharoen W. Plant molecular farming: a viable platform for recombinant biopharmaceutical production. Plants (Basel). 2020;9(7):842. doi:10.3390/plants9070842.
   PubMedGoogle Scholar
• Lobato Gómez M, Huang X, Alvarez D, He W, Baysal C, Zhu C, Armario‐Najera V, Blanco Perera A, Cerda Bennasser P, Saba‐Mayoral A, et al. Contributions of the international plant science community to the fight against human infectious diseases – part 1: epidemic and pandemic diseases. Plant Biotechnol J. 2021;19(10):1901–20. doi:10.1111/pbi.13657.
   PubMed Web of Science ®Google Scholar
• Phoolcharoen W, Shanmugaraj B, Khorattanakulchai N, Sunyakumthorn P, Pichyangkul S, Taepavarapruk P, Praserthsee W, Malaivijitnond S, Manopwisedjaroen S, Thitithanyanont A, et al. Preclinical evaluation of immunogenicity, efficacy and safety of a recombinant plant-based SARS-CoV-2 RBD vaccine formulated with 3M-052-Alum adjuvant. Vaccine. 2023;41(17):2781–92. doi:10.1016/j.vaccine.2023.03.027.
   PubMed Web of Science ®Google Scholar
• Graham BS. Vaccine development for respiratory syncytial virus. Curr Opin Virol. 2017;23:107–12. doi:10.1016/j.coviro.2017.03.012.
   PubMed Web of Science ®Google Scholar
• Chen Q, He J, Phoolcharoen W, Mason HS. Geminiviral vectors based on bean yellow dwarf virus for production of vaccine antigens and monoclonal antibodies in plants. Hum Vaccin. 2011;7(3):331–8. doi:10.4161/hv.7.3.14262.
   PubMed Web of Science ®Google Scholar
• Boukhvalova MS, Mbaye A, Kovtun S, Yim KC, Konstantinova T, Getachew T, Khurana S, Falsey AR, Blanco JCG. Improving ability of RSV microneutralization assay to detect G-specific and cross-reactive neutralizing antibodies through immortalized cell line selection. Vaccine. 2018;36(31):4657–62. doi:10.1016/j.vaccine.2018.06.045.
   PubMed Web of Science ®Google Scholar
• Shahabi A, Peneva D, Incerti D, McLaurin K, Stevens W. Assessing variation in the cost of Palivizumab for respiratory syncytial virus prevention in preterm infants. PharmacoEconomics Open. 2018;2(1):53–61. doi:10.1007/s41669-017-0042-3.
   PubMed Web of Science ®Google Scholar
• Pogue GP, Vojdani F, Palmer KE, Hiatt E, Hume S, Phelps J, Long L, Bohorova N, Kim D, Pauly M, et al. Production of pharmaceutical-grade recombinant aprotinin and a monoclonal antibody product using plant-based transient expression systems. Plant Biotechnol J. 2010;8(5):638–54. doi:10.1111/j.1467-7652.2009.00495.x.
   PubMed Web of Science ®Google Scholar
• Xu J, Ge X, Dolan MC. Towards high-yield production of pharmaceutical proteins with plant cell suspension cultures. Biotechnol Adv. 2011;29(3):278–99. doi:10.1016/j.biotechadv.2011.01.002.
   PubMed Web of Science ®Google Scholar
• Nandi S, Kwong AT, Holtz BR, Erwin RL, Marcel S, McDonald KA. Techno-economic analysis of a transient plant-based platform for monoclonal antibody production. Mabs-austin. 2016;8(8):1456–66. doi:10.1080/19420862.2016.1227901.
   PubMed Web of Science ®Google Scholar
• Tusé D, Tu T, McDonald KA. Manufacturing economics of plant-made biologics: case studies in therapeutic and industrial enzymes. Biomed Res Int. 2014;2014:256135. doi:10.1155/2014/256135.
   PubMed Web of Science ®Google Scholar
• Walwyn DR, Huddy SM, Rybicki EP. Techno-economic analysis of horseradish peroxidase production using a transient expression system in Nicotiana benthamiana. Appl Biochem Biotechnol. 2015;175(2):841–54. doi:10.1007/s12010-014-1320-5.
   PubMed Web of Science ®Google Scholar
• Wilken LR, Nikolov ZL. Recovery and purification of plant-made recombinant proteins. Biotechnol Adv. 2012;30(2):419–33. doi:10.1016/j.biotechadv.2011.07.020.
   PubMed Web of Science ®Google Scholar
• Ridgley LA, Falci Finardi N, Gengenbach BB, Opdensteinen P, Croxford Z, Ma JK, Bodman‐Smith M, Buyel JF, Teh AYH. Killer to cure: expression and production costs calculation of tobacco plant-made cancer-immune checkpoint inhibitors. Plant Biotechnol J. 2023;21(6):1254–69. doi:10.1111/pbi.14034.
   PubMed Web of Science ®Google Scholar
• Werner RG. Economic aspects of commercial manufacture of biopharmaceuticals. J Biotechnol. 2004;113(1–3):171–82. doi:10.1016/j.jbiotec.2004.04.036.
   PubMed Web of Science ®Google Scholar
• Xenopoulos A. A new, integrated, continuous purification process template for monoclonal antibodies: process modeling and cost of goods studies. J Biotechnol. 2015;213:42–53. doi:10.1016/j.jbiotec.2015.04.020.
   PubMed Web of Science ®Google Scholar
• Zeitlin L, Bohorov O, Bohorova N, Hiatt A, Kim DH, Pauly MH, Velasco J, Whaley K, Barnard D, Bates J, et al. Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model. MAbs. 2013;5(2):263–9. doi:10.4161/mabs.23281.
   PubMed Web of Science ®Google Scholar
• Hiatt A, Bohorova N, Bohorov O, Goodman C, Kim D, Pauly MH, Velasco J, Whaley KJ, Piedra PA, Gilbert BE, et al. Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc Natl Acad Sci USA. 2014;111(16):5992–7. doi:10.1073/pnas.1402458111.
   PubMed Web of Science ®Google Scholar
• Loos A, Van Droogenbroeck B, Hillmer S, Grass J, Pabst M, Castilho A, Kunert R, Liang M, Arcalis E, Robinson DG, et al. Expression of antibody fragments with a controlled N-Glycosylation pattern and induction of endoplasmic reticulum-derived vesicles in seeds of arabidopsis. Plant Physiol. 2011;155(4):2036–48. doi:10.1104/pp.110.171330.
   PubMed Web of Science ®Google Scholar
• Triguero A, Cabrera G, Cremata JA, Yuen C-T, Wheeler J, Ramírez NI. Plant-derived mouse IgG monoclonal antibody fused to KDEL endoplasmic reticulum-retention signal is N-glycosylated homogeneously throughout the plant with mostly high-mannose-type N-glycans. Plant Biotechnol J. 2005;3(4):449–57. doi:10.1111/j.1467-7652.2005.00137.x.
   PubMed Web of Science ®Google Scholar